Ursolic acid improves survival and attenuates lung injury in septic rats induced by cecal ligation and puncture

Journal of Surgical Research

Volumn 194, Issue 2, 2015, Pages 528-536

  Hu, Zhansheng ^a   Gu, Zhilong ^a   Sun, Meina ^a   Zhang, Ke ^a   Gao, Penghui ^a   Yang, Qinwu ^a   Yuan, Yuan ^b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b Jinzhou Central Hospital   (China)

Author keywords

Acute lung injury; Inflammatory mediator; Sepsis; Survival; Ursolic acid

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; URSOLIC ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOKINE; NOS2 PROTEIN, RAT; PEROXIDASE; PLANT EXTRACT; PTGS2 PROTEIN, RAT; TRITERPENE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS MUCOSA; CECAL LIGATION AND PUNCTURE; CONTROLLED STUDY; DRY WEIGHT; ENZYME ACTIVITY; HISTOLOGY; INFLAMMATORY CELL; LUNG ALVEOLUS EPITHELIUM; LUNG CONGESTION; LUNG EDEMA; LUNG WEIGHT; LYMPHOCYTIC INFILTRATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEPSIS; SURGICAL TECHNIQUE; SURVIVAL; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; LUNG; METABOLISM; PHYTOTHERAPY; PRECLINICAL STUDY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ACUTE LUNG INJURY; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOMARKERS; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; LUNG; MALE; MALONDIALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; PHYTOTHERAPY; PLANT EXTRACTS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; SEPSIS; TRITERPENES;

EID: 84924901783     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.10.027     Document Type: Article

References (44)

1. E. Abraham, and M. Singer Mechanisms of sepsis-induced organ dysfunction Crit Care Med 35 2007 2408
2. M.R. Pinsky Sepsis and multiple organ failure Contrib Nephrol 156 2007 47
3. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303
4. M.C. Strehlow, S.D. Emond, N.I. Shapiro, A.J. Pelletier, and C.A. Camargo Jr. National study of emergency department visits for sepsis, 1992 to 2001 Ann Emerg Med 48 2006 326 331.e1-3
5. C.C. Sheu, M.N. Gong, and R. Zhai Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS Chest 138 2010 559
6. J. Liu Pharmacology of oleanolic acid and ursolic acid J Ethnopharmacol 49 1995 57
7. W. Liu, X. Tan, and L. Shu Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial cell injury and prevents development of lung cancer Molecules 17 2012 9104
8. M.A. Vasconcelos, V.A. Royo, and D.S. Ferreira In vivo analgesic and anti-inflammatory activities of ursolic acid and oleanoic acid from Miconia albicans (Melastomataceae) Z Naturforsch C 61 2006 477
9. S.H. Kim, J.H. Hong, and Y.C. Lee Ursolic acid, a potential PPARgamma agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma Eur J Pharmacol 701 2013 131
10. Z.Q. Su, Z.Z. Mo, and J.B. Liao Usnic acid protects LPS-induced acute lung injury in mice through attenuating inflammatory responses and oxidative stress Int Immunopharmacol 22 2014 371
11. M.K. Shanmugam, X. Dai, A.P. Kumar, B.K. Tan, G. Sethi, and A. Bishayee Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies Biochem Pharmacol 85 2013 1579
12. S.F. Ahmad, B. Khan, S. Bani, K.A. Suri, N.K. Satti, and G.N. Qazi Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production Pharm Res 53 2006 233
13. J. Chun, C. Lee, S.W. Hwang, J.P. Im, and J.S. Kim Ursolic acid inhibits nuclear factor-kappaB signaling in intestinal epithelial cells and macrophages, and attenuates experimental colitis in mice Life Sci 110 2014 23
14. X. Chen, Y. Wan, T. Zhou, J. Li, and Y. Wei Ursolic acid attenuates lipopolysaccharide-induced acute lung injury in a mouse model Immunotherapy 5 2013 39
15. D. Rittirsch, M.S. Huber-Lang, M.A. Flierl, and P.A. Ward Immunodesign of experimental sepsis by cecal ligation and puncture Nat Protoc 4 2009 31
16. R.F. Guo, and P.A. Ward Role of oxidants in lung injury during sepsis Antioxid Redox Signal 9 2007 1991
17. D. Rittirsch, L.M. Hoesel, and P.A. Ward The disconnect between animal models of sepsis and human sepsis J Leukoc Biol 81 2007 137
18. A.M. Fein, and M.G. Calalang-Colucci Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock Crit Care Clin 16 2000 289
19. S. Tasaka, N. Hasegawa, and A. Ishizaka Pharmacology of acute lung injury Pulm Pharmacol Ther 15 2002 83
20. K.P. Steinberg, J.A. Milberg, T.R. Martin, R.J. Maunder, B.A. Cockrill, and L.D. Hudson Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome Am J Respir Crit Care Med 150 1994 113
21. J. Grommes, and O. Soehnlein Contribution of neutrophils to acute lung injury Mol Med 17 2011 293
22. M. Christofidou-Solomidou, and V.R. Muzykantov Antioxidant strategies in respiratory medicine Treatments Respir Med 5 2006 47
23. S. Martin-Aragon, B. de las Heras, M.I. Sanchez-Reus, and J. Benedi Pharmacological modification of endogenous antioxidant enzymes by ursolic acid on tetrachloride-induced liver damage in rats and primary cultures of rat hepatocytes Exp Toxicol Pathol 53 2001 199
24. D.L. Chong, and S. Sriskandan Pro-inflammatory mechanisms in sepsis Contrib Microbiol 17 2011 86
25. S.Q. Simpson, and L.C. Casey Role of tumor necrosis factor in sepsis and acute lung injury Crit Care Clin 5 1989 27
26. M. Bhatia, and S. Moochhala Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome J Pathol 202 2004 145
27. N.C. Riedemann, T.A. Neff, and R.F. Guo Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression J Immunol 170 2003 503
28. L.L. Moldawer Interleukin-1, TNF alpha and their naturally occurring antagonists in sepsis Blood Purif 11 1993 128
29. J. Lomas-Neira, M. Perl, F. Venet, C.S. Chung, and A. Ayala The role and source of tumor necrosis factor-alpha in hemorrhage-induced priming for septic lung injury Shock 37 2012 611
30. T. Vanden Berghe, D. Demon, and P. Bogaert Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock Am J Respir Crit Care Med 189 2014 282
31. H. Ruetten, and C. Thiemermann Combination immunotherapy which neutralises the effects of TNF alpha and IL-1 beta attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat J Physiol Pharmacol 48 1997 605
32. N. Aikawa, T. Takahashi, and S. Fujimi A phase II study of polyclonal anti-TNF-alpha (AZD9773) in Japanese patients with severe sepsis and/or septic shock J Infect Chemother 19 2013 931
33. S.F. Ang, S.W. Sio, S.M. Moochhala, and P.A. MacAry Bhatia M hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation J Immunol 187 2011 4778
34. W. Ertel, M.H. Morrison, P. Wang, Z.F. Ba, A. Ayala, and I.H. Chaudry The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins Ann Surg 214 1991 141
35. S. Shishodia, D. Koul, and B.B. Aggarwal Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis J Immunol 173 2004 2011
36. P. Lirk, G. Hoffmann, and J. Rieder Inducible nitric oxide synthase-time for reappraisal Curr Drug Targets Inflamm Allergy 1 2002 89
37. K.S. Farley, L.F. Wang, and H.M. Razavi Effects of macrophage inducible nitric oxide synthase in murine septic lung injury Am J Physiol Lung Cell Mol Physiol 290 2006 L1164
38. V.E. Laubach, E.G. Shesely, O. Smithies, and P.A. Sherman Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death Proc Natl Acad Sci U S A 92 1995 10688
39. S. Moncada, R.M. Palmer, and E.A. Higgs Nitric oxide: physiology, pathophysiology, and pharmacology Pharmacol Rev 43 1991 109
40. A.H. Abdelazeem, S.A. Abdelatef, and M.T. El-Saadi Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; design, synthesis and biological evaluation as potential anti-inflammatory agents Eur J Pharm Sci 62 2014 197
41. L. Sautebin Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy Fitoterapia 71 Suppl 1 2000 S48
42. K. Subbaramaiah, P. Michaluart, M.B. Sporn, and A.J. Dannenberg Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells Cancer Res 60 2000 2399
43. N. Suh, T. Honda, and H.J. Finlay Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages Cancer Res 58 1998 717
44. L. Dejager, I. Pinheiro, E. Dejonckheere, and C. Libert Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 19 2011 198